DURHAM, N.C. --(BUSINESS WIRE)--Jun. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022 , respectively...